Sub-Domains within Public Health

1 Public Health Infrastructure & Governance The federal architecture of HHS-CDC-FDA, the state architecture of PA DOH operating under the Disease Prevention and Control Law of 1955 (35 P.S. §§ 521.1-521.21) and 28 Pa. Code Title 28, and the local architecture of PDPH operating under Philadelphia Code Title 6 and the Home Rule Charter. Three federal-disruption patterns operate during the verification window: capacity erosion (FDA RIF refined to approximately 18% of workforce, approximately 25% HHS aggregate when voluntary separations counted; Rhode Island injunction narrowed scope August 12, 2025); governance disruption (ACIP charter renewal April 9, 2026 plus Decision Memo schedule reduction January 5, 2026); federalism stress (PPHF cumulative rescission approximately $11.85 billion FY13-FY27; FY26 elimination proposed). 2 Communicable Disease Control The federal disease-reporting and immunization architecture (PHSA § 247b PHEP; § 247d PHE declaration authority; § 317 immunization program; ACIP/VFC; Ryan White; ACA § 2713 preventive services), the state framework (28 Pa. Code §§ 27.1-27.166 reportable diseases; 28 Pa. Code Chapter 23 Subchapter C school immunizations), and the local framework (PDPH Communicable Disease Control division; AACO Philadelphia EMA Ryan White Part A). The Braidwood resolution (June 27, 2025) preserves USPSTF preventive services nationwide; the Murphy preliminary injunction restores the pre-January 2026 federal childhood schedule including hep B birth-dose. The HHS mRNA wind-down (August 5, 2025; 22 BARDA contracts terminated, approximately $500M) and the CDC Immunization Services Division termination (excluded from the August 12, 2025 narrowing of the Rhode Island injunction) constrain federal communicable-disease infrastructure capacity. 3 Maternal & Child Health The federal block-grant architecture (Title V MCH Block Grant; SSA § 501; HRSA-MCHB administered) plus categorical programs (EPSDT; MIECHV; Healthy Start; Preventing Maternal Deaths Act of 2018; Newborn Screening Saves Lives Reauthorization Act of 2014) layered over state programs (PA Newborn Screening Program at 28 Pa. Code § 28.4; PA Maternal Mortality Review Committee (MMRC) under Act 24 of 2018) and local Philadelphia programs (FIMR under PDPH MCFH division). The Braidwood resolution preserves perinatal preventive services USPSTF coverage; the Murphy injunction restores hep B birth-dose recommendations. 4 Chronic & Non-Communicable Disease The federal architecture of ACA § 2713 preventive services (Braidwood-resolved), the IRA Medicare Drug Price Negotiation Program (Round 1 effective January 1, 2026 with 10 drugs at MFP discounts of 38-79%; Round 2 prices effective January 1, 2027; Round 3 in progress with OBBBA orphan-drug exclusion expansion delaying Keytruda and Opdivo selections), the Tobacco Control Act / FSPTCA plus CTP menthol withdrawal (RIN 0910-AI60 January 21, 2025; CTP protected by the Rhode Island injunction), Trump EO 14273 (April 15, 2025; IRA continues under modification), and CDC PLACES chronic-disease surveillance. State and local layers: PA Cancer Control Plan; PA Cancer Registry; Philadelphia Sweetened Beverage Tax; Philadelphia Tobacco Retailer Licensing. 5 Environmental Health The federal statutory architecture of the Clean Air Act, SDWA + LCRR, Residential Lead-Based Paint Hazard Reduction Act of 1992, and CERCLA / Superfund. The environmental justice framework that historically integrated these statutes — EO 12898 (Clinton 1994), EO 14008 § 219 Justice40 (Biden 2021), EO 14096 (Biden 2023) — was substantially rolled back through three Trump EOs (14148, 14151, 14173) on January 20-21, 2025; EPA implementation on March 12, 2025 closed the EPA Office of Environmental Justice and External Civil Rights and EJ units in all 10 EPA regions including Region III; EJScreen was taken offline. State framework continues operative (PA Air Pollution Control Act; PA SDWA; PA Act 2 of 1995; PA HSCA; PA Lead Paint Abatement Act of 1994; PA Const. Article I § 27 + PEDF). Local: Philadelphia Lead Disclosure Law continues operative. 6 Health Access, FQHCs & SDOH The federal architecture of PHSA § 330 (FQHC program), HPSA/MUA designation, NHSC/Nurse Corps, EMTALA, Medicaid managed care plus 42 C.F.R. Part 438, Title VI / EO 13166 language access, ACA § 9007 plus IRC § 501(r) community benefit, and the 340B Drug Pricing Program. FQHC § 330 mandatory funding extended through December 2026 via the 2026 Consolidated Appropriations Act; no multi-year reauthorization despite advocate push; OBBBA Medicaid cuts threaten FQHC financial stability multi-year (Medicaid is 40%+ of FQHC revenue). Temple Health and Einstein recharacterized from "closure-scenario indicators" to "operational financial pressure under federal Medicaid uncertainty"; Temple FY25 $22M operating profit; investment-grade BBB rating maintained. PA-3 FQHC roster: Philadelphia FIGHT, Puentes de Salud, MANNA, RHD, Family Practice & Counseling Network. 7 Substance Use & Harm Reduction The federal architecture of the CSA plus § 856, the DEA Schedule III rescheduling Final Order (signed April 22-23, 2026; effective approximately April 28, 2026), Trump EO 14370 (December 18, 2025), § 280E IRC plus Treasury press release April 23, 2026, the SUPPORT Act of 2018, the MAT Act of 2023, FDA naloxone OTC (March 2023), and SAMHSA OTP regulations 42 C.F.R. Part 8. State framework: PA Act 66 of 2021 (Syringe Service Program authorization); PA Act 139 of 2014 (Good Samaritan); PDMP Acts 191/53. Local framework: DBHIDS HealthChoices Behavioral Health single-MCO model; Prevention Point Philadelphia. Philadelphia overdose deaths trajectory: 2022 peak 1,376 → 2024 1,045 → 2025 preliminary 747; PA 2025 preliminary 2,178 (-29%). Demographic disparity persists: Black rates continued rising through 2024 while White rates declined.